The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.

ABSTRACT:

Background

N-Acetylgalactosaminyltransferases (GALNTs), the enzymes that initiate mucin-type O-glycosylation, are closely associated with tumor occurrence and progression. However, a comprehensive analysis of GALNTs in non-small cell lung cancer (NSCLC) is lacking.

Methods

The expression profiles and prognostic values of the GALNT family members in NSCLC were analyzed using publicly available databases. Gain- and loss-of-function experiments were applied to assess the biological function of GALNT2 in NSCLC. High-throughput sequencing and bioinformatics approaches were employed to uncover the regulatory mechanism of GALNT2.

Results

Among the family members of GALNTs, only GALNT2 was frequently overexpressed in NSCLC tissues and was positively correlated with poor progn

SUBMITTER: Hu Q 

PROVIDER: S-EPMC9440866 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature